Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ARO-ALK7 · 1 trial · 2 indications
| Arm | Type | Description |
|---|---|---|
| Part 1 and Part 2 (optional cohort): ARO-ALK7 | EXPERIMENTAL | ARO-ALK7 in single (Day 1) or multiple (Days 1 and 85) ascending doses |
| Part 1 and Part 2 (optional cohort): Placebo | PLACEBO_COMPARATOR | Placebo in single (Day 1) or multiple (Days 1 and 85) matching doses |
| Part:2: ARO-ALK7 + Tirzepatide | EXPERIMENTAL | ARO-ALK7 at ascending doses on Days 1 and 85 plus weekly doses of tirzepatide initiated at Day 15 through Day 253 |
| Part 2: Placebo + Tirzepatide | PLACEBO_COMPARATOR | Placebo dose on Days 1 and 85 plus weekly doses of tirzepatide initiated at Day 15 through Day 253 |
| Name | Type | Description |
|---|---|---|
| ARO-ALK7 | DRUG | Subcutaneous (SC) injection |
| Placebo | DRUG | calculated volume to match active treatment by SC injection |
Inclusion Criteria: * Obesity, defined as body mass index (BMI) between 30-50 kilograms (kg)/square meter (m\^2), inclusive, with weight at Screening not to exceed 159 kg (350 pounds \[lbs\]) * At least one self-reported, unsuccessful attempt at weight loss with lifestyle modification * No abnormal...
Top 20 of 35 competitors
ARO-ALK7 is an investigational drug being developed for the treatment of obesity. It is also being studied in adults with obesity who have type 2 diabetes mellitus. The drug is currently in Phase 1 clinical development.
ARO-ALK7 targets ALK7, a molecular target involved in metabolic regulation. By targeting ALK7, the drug aims to address obesity and related metabolic conditions. The specific mechanism of action is under investigation in clinical trials.
ARO-ALK7 is being developed by Arrowhead Pharmaceuticals, Inc., a biopharmaceutical company. Arrowhead is conducting clinical trials to evaluate the safety and efficacy of ARO-ALK7 in adults with obesity.
ARO-ALK7 is in Phase 1 clinical development. It is an investigational drug and has not yet been approved by regulatory authorities. The Phase 1 trial is currently recruiting participants to assess the drug's safety and tolerability.
ARO-ALK7 is being studied in a Phase 1 first-in-human trial with the identifier NCT06937203. The trial is recruiting 150 adults with obesity, with or without type 2 diabetes, at sites in Australia and New Zealand. It is a randomized, double-blind, placebo-controlled study.
ARO-ALK7 is a distinct investigational drug candidate developed by Arrowhead Pharmaceuticals. It is not known to be the same as any other approved or marketed medication. Its unique molecular target and development program differentiate it from other obesity treatments.